Previous close | 1,641.50 |
Open | 1,643.00 |
Bid | 1,642.50 x 0 |
Ask | 1,642.00 x 0 |
Day's range | 1,626.00 - 1,656.00 |
52-week range | 1,261.00 - 1,656.00 |
Volume | |
Avg. volume | 330,290 |
Market cap | 2.552T |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 37.27 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 30.74 (1.87%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.